Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

Results of GSK and AstraZeneca trials may widen ovarian cancer drug use
Reuters: Health
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.


Comments

Popular posts from this blog

Nadda reviews healthcare delivery mechanisms in Rajasthan, Maharashtra

Women in India Report Higher Sleep Deprivation Than Men

Ayush no longer at margins but at centre of global health discourse: Prataprao Jadhav